Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian Berger

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Ophthalmology. Retina|May 4, 2019
A Randomized Phase 2 Study of an Anti-Amyloid β Monoclonal Antibody in Geographic Atrophy Secondary to Age-Related Macular DegenerationPhilip J Rosenfeld, Brian Berger, Elias Reichel, et al.
Ophthalmology Science|May 1, 2026
Assessing the Safety and Efficacy of Agonistic Monoclonal Antibody against Robo4 versus Ranibizumab in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Phase I, Open-Label, Multicenter StudyRubbia Afridi, Giorgio Senaldi, Jaclyn Joyce Hwang, et al.
Ophthalmology Science|January 13, 2025
CANBERRA: A Phase II Randomized Clinical Trial to Test the Therapeutic Potential of Oral Vicasinabin in Diabetic RetinopathyBeatriz G Armendariz, Ulrich F O Luhman, Brian Berger, et al.
Cell Stem Cell|October 11, 2011
Impracticality of egg donor recruitment in the absence of compensationDieter Egli, Alice E Chen, Genevieve Saphier, et al.
International Journal of Retina and Vitreous|August 8, 2019
Primary outcomes of the VIDI study: phase 2, double-masked, randomized, active-controlled study of ASP8232 for diabetic macular edemaQuan Dong Nguyen, Yasir J Sepah, Brian Berger, et al.
Mabs|February 28, 2019
Integrin α-3 ß-1's central role in breast cancer, melanoma and glioblastoma cell aggregation revealed by antibodies with blocking activityDaniel F Lusche, Michael R Klemme, Benjamin A Soll, et al.
JAMA Ophthalmology|July 31, 2020
Safety and Efficacy of Different Doses and Regimens of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The AVENUE Phase 2 Randomized Clinical TrialJayashree Sahni, Pravin U Dugel, Sunil S Patel, et al.
Ophthalmology|March 4, 2023
Archway Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration 2-Year ResultsCarl Regillo, Brian Berger, Logan Brooks, et al.
Bioinformatics (Oxford, England)|July 23, 2003
ESTprep: preprocessing cDNA sequence readsTodd E Scheetz, Nishank Trivedi, Chad A Roberts, et al.
Genome Research|October 19, 2004
1274 full-open reading frames of transcripts expressed in the developing mouse nervous systemMaria F Bonaldo, Thomas B Bair, Todd E Scheetz, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Ophthalmology. Retina|May 4, 2019
A Randomized Phase 2 Study of an Anti-Amyloid β Monoclonal Antibody in Geographic Atrophy Secondary to Age-Related Macular DegenerationPhilip J Rosenfeld, Brian Berger, Elias Reichel, et al.
Ophthalmology Science|May 1, 2026
Assessing the Safety and Efficacy of Agonistic Monoclonal Antibody against Robo4 versus Ranibizumab in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Phase I, Open-Label, Multicenter StudyRubbia Afridi, Giorgio Senaldi, Jaclyn Joyce Hwang, et al.
Ophthalmology Science|January 13, 2025
CANBERRA: A Phase II Randomized Clinical Trial to Test the Therapeutic Potential of Oral Vicasinabin in Diabetic RetinopathyBeatriz G Armendariz, Ulrich F O Luhman, Brian Berger, et al.
Cell Stem Cell|October 11, 2011
Impracticality of egg donor recruitment in the absence of compensationDieter Egli, Alice E Chen, Genevieve Saphier, et al.
International Journal of Retina and Vitreous|August 8, 2019
Primary outcomes of the VIDI study: phase 2, double-masked, randomized, active-controlled study of ASP8232 for diabetic macular edemaQuan Dong Nguyen, Yasir J Sepah, Brian Berger, et al.
Mabs|February 28, 2019
Integrin α-3 ß-1's central role in breast cancer, melanoma and glioblastoma cell aggregation revealed by antibodies with blocking activityDaniel F Lusche, Michael R Klemme, Benjamin A Soll, et al.
JAMA Ophthalmology|July 31, 2020
Safety and Efficacy of Different Doses and Regimens of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The AVENUE Phase 2 Randomized Clinical TrialJayashree Sahni, Pravin U Dugel, Sunil S Patel, et al.
Ophthalmology|March 4, 2023
Archway Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration 2-Year ResultsCarl Regillo, Brian Berger, Logan Brooks, et al.
Bioinformatics (Oxford, England)|July 23, 2003
ESTprep: preprocessing cDNA sequence readsTodd E Scheetz, Nishank Trivedi, Chad A Roberts, et al.
Genome Research|October 19, 2004
1274 full-open reading frames of transcripts expressed in the developing mouse nervous systemMaria F Bonaldo, Thomas B Bair, Todd E Scheetz, et al.
Pageof 3